Molecular Partners AG

Healthcare · Biotechnology · Switzerland

Last price 3.53 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 138.60M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (D...